One purported advantage of electronic medical records (EMRs) is to improve patient care. This study uses a search of EMR to identify patients at risk for prostate cancer who were not evaluated by an urologist. The University of Texas Southwestern Medical Center (UTSW) has an institutional outpatient EMR that is used by all providers in all specialties. Since March 2009, all PSA tests were reported with specific interpretative comments including a recommendation for referral to urology for a PSA 42.5 ng ml
Introduction
The introduction of electronic medical records (EMRs) was intended to improve patient care by improving communication between clinicians, improving access of health information to patients, and identifying potential drug interactions and abnormal laboratory values. These are lofty goals but the day-to-day application is still unclear especially when applied to improving quality of care. One potential area of improvement can be through institution of guidelines for management of certain diseases that would trigger evaluation. This could be particularly helpful in multispecialty clinics where EMR bridges patient care across specialties. As of yet, there is little evidence of how well use of EMR performs in this function.
In the past three decades, advancements in prostate cancer management have lead to a decrease in the number of patients presenting with late-stage disease at diagnosis and an encouraging 33% decrease in annual mortality in the United States due to prostate cancer. 1 The role of serum PSA screening in these advancements is still controversial, [2] [3] [4] [5] and recommendations regarding its use as a screening tool are frequently changing. 6 Despite its imperfections, PSA screening is still widely used by urologists and primary care physicians alike. In 2000, the National Health Interview Survey showed that 33.6% of all U.S. men aged 50-64 years and 51.3% of men aged X65 reported having a PSA test within the previous year, 7 and one study has suggested that as many as 75% of men over 50 years of age undergo regular PSA screening. 8 Although the aggressive use of PSA screening in the early 1990's could have contributed to the decline in late-stage diagnosis and mortality that was previously seen with prostate cancer, it has also led to a twofold increase in total prostate cancer incidence and an increase in overdiagnosis and overtreatment. 5, [9] [10] [11] The difficulty of using serum PSA as a screening test lies in its inability to reliably differentiate benign elevations in PSA from prostate cancer, the uncertainty regarding an optimal cutoff point and recent evidence that some men with 'normal' PSA values have prostate cancer. [12] [13] [14] Proposed age-and race-adjusted PSA ranges have been met with some resistance, as have the use of other assays, including free/total PSA ratio, complexed PSA and PSA/transitional zone PSA density which, like PSA screening, also relies on poorly defined ranges and threshold values. 15, 16 Owing to the complexity of PSA screening, the American Urological Association released an updated PSA Best Practice Statement in 2009 which now recommends that all men have a baseline serum PSA level drawn at age 40 instead of 50, that the previous threshold of 4.0 ng ml À1 for prostate biopsy be discarded, and that PSA and digital rectal exam screening be combined with free and total PSA, patient age, PSA velocity, PSA density, family history, ethnicity, previous biopsy history and comorbidities when assessing a patient's risk for prostate cancer and necessity to pursue biopsy and treatment. Risk calculators have been developed which use these personalized values in place of relying on a generalized threshold value, and are freely available online. [17] [18] [19] [20] This type of patient-oriented, tailored approach which eliminates traditional thresholds may assist in the dialogue between physician and patient on what course of management is best for that particular patient, on the basis of evidence-based medicine and the informed patient's personal preference.
The University of Texas Southwestern Medical Center (UTSW) uses a computerized EMR for all inpatient and outpatient encounters. Starting in March 2009, interpretive comments were given and recommendations were made to refer patients with a PSA 42.5 ng ml À1 to an urologist for consultation regarding management. This information accompanies every PSA laboratory report either online or in print. The goal of this study was to evaluate the clinical management of patients with elevated PSA after initiation of this recommendation.
Materials and methods
The EMR at the UTSW was queried for all patients who underwent a PSA test for any reason between March 2009 and February 2010. The study was approved by the institutional review board at UTSW. Patients were initially stratified by whether they were seen in the urology clinic or outside of urology. Patients with at least one office visit in urology between March 2009 and February 2010 were considered a urology patient for the purpose of this analysis. Charts were reviewed for all patients with a PSA 42.5 ng ml À1 that were not seen by an urologist. In order to identify patients who were seen only by non-urologists, we excluded patients seen by an urologist at UTSW, an outside urologist or with a known history of prostate cancer who was seeing an oncologist at our institution. We assumed that men aged 40-60 years would most likely benefit from evaluation of elevated PSA as their life expectancy would likely exceed 15 years while PSA is likely not indicated in men aged 80 years because of life expectancy that is unlikely to reach 15 years.
Information gathered from records of the patients for analysis included: the last PSA level of the patients and the date it was drawn, the previous PSA level and the date it was drawn (if any was available), the rise in PSA and PSA velocity (if more than one PSA was available), age of the patients, ethnicity and family history of prostate cancer and whether they had had a prostate biopsy.
Results
There were 5414 male patients who had serum PSA levels drawn between March 2009 and February 2010 at UTSW. Figure 1 shows the stratification of patients in the cohort. There were 2530 patients seen in the urology clinic and 2884 patients seen in non-urology clinics. Of the 2884 non-urology patients, 300 were found to have a serum PSA 42.5 ng ml À1 and were included in the study (see Table 1 ). Seven patients died of non-prostate cancerrelated causes during the study period and were excluded from study. An additional 39 patients were found to have previously diagnosed prostate cancer and were excluded. Of the 254 patients without diagnosed prostate cancer and a serum PSA 42.5 ng ml À1 , 59 patients were found to be either seeing an urologist or had seen an urologist within a year before the last drawn PSA and had not seen a rise in their PSA greater than 0.5 ng ml 2884 Non-Urology patients (see Table 1 Figure 1 Breakdown of patients by exclusion criteria.
Use
patients who were seen only in non-urology clinics (see Table 2 ). In all, 73.3% of these patients had a PSA between 42.5 and p4.0, of which the majority were men aged 60 and 70 years (70.7%). However, 23.8% were younger men aged 40 and 50 years. Of the 25.1% of men with PSA values 44.0 and p10.0, the majority again were aged 60 and 70 years (75.5%) with an increasing proportion of men aged 80 years (14.3%). Overall, 61% of men (those aged 40, 50 and 60 years) would most likely benefit from a urological consultation, while only 7.7% (those aged 80 years) likely had a PSA test performed that was not indicated (see Table 2 ).
In reviewing the EMR of these patients, 11 patients were referred to urology by their outside physician but there is no evidence that they saw an urologist. The remaining 184 patients were not referred to urology, and had either never previously seen an urologist, or had not seen an urologist within 1 year of their serum PSA level increasing to above 2.5 ng ml À1 . Of the 195, only 9 patients had a previously documented negative prostate biopsy in their chart, with the most recent biopsy having been performed more than 2 years before their current PSA. There were 24 patients (12.3%) of the 195 with a positive family history for prostate cancer. A family history was recorded for all 195 patients.
There were 151 patients with an additional previous PSA value in our EMR and 103 (68.2%) of these 151 men were found to have a rise in serum PSA over their previous value. The median increase in PSA was 0.53 ng ml À1 per year and a range of 0.01-35.24 ng ml
À1
per year. There were 40 (26.5%) men with a PSA velocity 40.75 ng ml À1 per year, a threshold value introduced in the past as being suspicious for prostate cancer. 21 Of the 44 men with only one PSA in our records, the average initial PSA was found to be 3.9 ng ml À1 (s ¼ 1.5).
Discussion
The utilization of EMRs in multispecialty clinics has the potential to improve performance of quality control and use of evidence-based medicine. In light of controversial guidelines regarding optimal use of PSA, the urology and clinical chemistry departments at UTSW agreed on a set of interpretive comments/recommendations at our institution, including one that patients with a PSA 42.5 ng ml À1 be evaluated by an urologist. Although use of any particular cutoff point for PSA is not established as optimal, the recognition that many patients with a serum PSA over 2.5 ng ml À1 have prostate cancer makes discussion of prostate cancer risks with an informed provider necessary. 12, [17] [18] [19] There are several interesting findings in this study. First, non-urologist physicians ordered PSA tests on 2884 men in 1 year's time at our institution. Second, most PSA tests were performed on patients between the ages of 50 and 70 but 11 and 4% were done in men under age 50 and over age 80, respectively, which falls outside the age range for PSA testing recommendations by various authoritative bodies. We found that 195 men with a PSA 42.5 ng ml À1 were not referred to an urologist and did not have documentation of a discussion regarding their PSA and potential risk for prostate cancer. Of these, 103 (68.2%) men were found to have a rise in serum PSA over their previous value with a median increase in PSA of 0.53 ng ml À1 per year. There were 40 (26.5%) men with a PSA velocity 40.75 ng ml À1 per year. Men with a PSA 42 ng ml À1 have over a 23% chance of having prostate cancer and 19% of having high-grade prostate cancer. 12 As such, one would expect that some of these patients may harbor clinically significant disease.
The introduction of EMR was intended to improve patient care by improving communication between clinicians, improving access of health information to patients, and identifying potential drug interactions and abnormal laboratory values. Unfortunately, there are also concerns that use of EMR will lead to pitfalls from reliance on templates which can automatically populate fields, including laboratory values. 22 Although this study does not allow evaluation of whether recommendations to refer patients with a PSA 42.5 ng ml À1 influenced non-urologist physicians, one can use EMR to identify those patients who were not referred for further evaluation or who lack a documented discussion of the pros and cons of further evaluation. It is clear that even if discussions were held with patients, then there is a significant absence of documentation within the medical records of the occurrence of these discussions. Several other studies have also found that discussion of prostate cancer screening is often lacking. A study by Guerra et al. 23 found that prostate cancer screening discussion occurred in only 36% patient-physician encounters when patients were due for prostate cancer screening. Barriers to discussion were patient comorbidity, limited education/ health literacy, previous refusal of care, physician It is important to note that the goal of this study was not to advocate for the use of PSA screening, whose benefits are still questioned by some. 5, 12 It should be recognized, however, that many physicians order PSA routinely for their patients. As noted above, PSA tests were performed in 2884 men in 1 year's time by physicians who were not urologists. Most would agree that once a test is ordered, the results should be pursued or discussed appropriately. A study by McFall and Smith evaluated diagnostic follow-up for patients with abnormal PSA tests using data from the 2000 National Health Interview Survey cancer control supplement. 25 Approximately 15% of men with abnormal PSA tests reported no follow-up and this was more likely in Hispanic men and those without insurance. Men with a family history of prostate cancer or higher perceived risk of cancer were more likely to have appropriate follow-up. Our cohort consisted entirely of patients with insurance, and 12% had a family history of prostate cancer. Furthermore, 68% of men with previous PSA testing experienced a significant rise in PSA that might have raised the level of concern.
One limitation of this study was the fact that we cannot assess the denominator of patients. Those patients who were appropriately referred would have seen an urologist and were excluded from analysis. As such, the magnitude of the problem is difficult to assess. However, the optimal situation would be to appropriately evaluate all patients and as such, there is room for improvement. Our goal is to prospectively use our EMR to identify patients with elevated PSA and then notify physicians individually regarding abnormal PSA results. We will then be able to determine whether this reduces the number of patients who do not have appropriate discussion of their prostate cancer risks. Another limitation is that the EMR history is totally reliant on what has already been entered into the EMR for a given patient. It is possible that a number of men have seen urologists elsewhere but for one reason or not, the information not entered or that family history of prostate cancer may be missing.
In conclusion, a significant number of patients are being screened for prostate cancer by non-urologist physicians. Some patients with serum PSA levels 42.5 ng ml À1 are not referred to an urologist despite increased risk for prostate cancer. EMR can be helpful in identifying patients at risk and may improve prostate cancer detection.
